Is NEXGEL, Inc. (NXGL) a Buy, Sell, or Hold?
NASDAQ : NXGL
NEXGEL, Inc. — News
$0.38 USD
$0.04 (12.09%)
- Volume
- 170.42K
- Average Volume
- 253.41K
- Market Capitalization
- $3.22M
- P/E Ratio
- -0.96
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $2.89
- Year Low
- $0.33
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.70
| Source | Headline |
|---|---|
|
NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th
LANGHORNE, Pa. , June 04, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the Planet MicroCap Conference on June 16 - 18, 2026, in Las Vegas, NV. globenewswire.com - 2026-06-04 09:00:00 |
|
NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration
The study concluded that NEXGEL's hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to the control The study was published in Lasers in Surgery and Medicine, 2026 LANGHORNE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced positive data from the randomized, 30-patient, single-center Institutional Review Board (IRB) clinical study, funded by Innovative Optics, a leading supplier of safety products and personal protective equipment for medical, surgical and aesthetic healthcare facilities globally. globenewswire.com - 2026-05-19 09:00:00 |
|
NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript
NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript seekingalpha.com - 2026-05-15 14:10:45 |
|
NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical
Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Dave Hazard as Vice President of Sales for BIONX Surgical, a division of NEXGEL. globenewswire.com - 2026-05-13 08:30:00 |
|
NEXGEL To Report First Quarter 2026 Financial Results on May 15th
Management Will Host a Conference Call at 12:00 P. M. ET on the Same Day LANGHORNE, Pa. , May 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2026 ended March 31, 2026, on Friday, May 15, 2026. globenewswire.com - 2026-05-12 10:27:00 |
|
NEXGEL To Report First Quarter 2026 Financial Results on May 15th
Management Will Host a Conference Call at 12:00 P.M. ET on the Same Day LANGHORNE, Pa. globenewswire.com - 2026-05-12 10:27:00 |
